Oxylanthanum Carbonate
Phase 3UNI-494
Aliases: OLCLanthanum carbonateUNI-494
Source: Company Disclosure·Trials: 2
Modality
Small Molecule
MOA
Phosphate Binder
Target
GI Phosphate
Pathway
Lipid Met
CKD
Development Pipeline
Preclinical
~Jun 2018
→ ~Sep 2019
Phase 1
~Dec 2019
→ ~Mar 2021
Phase 2
~Jun 2021
→ ~Sep 2022
Phase 3
Dec 2022
→ May 2026
Phase 3Current
NCT04629456
1,262 pts·CKD
2022-12→2026-05·Completed
NCT07991010
571 pts·CKD
2024-03→TBD·Completed
1,833 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-05-182mo awayPh3 Readout· CKD
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P3
Complet…
P3
Complet…
Catalysts
Ph3 Readout
2026-05-18 · 2mo away
CKD
Completed|StartCompletionToday
Trials (2)